Role of Skin Cleansing and Prophylactic Antibiotic in Preventing Infectious Morbidity After Cesarean Section Delivery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Women undergoing cesarean delivery, both elective and non-elective.
- Rupture of membranes and labor contractions will be allowed.
Exclusion Criteria:
- Unknown outcome from the patient.
- Refusing to participate in the study from the admission conse
- Allergy to antibiotics.
- Any visible infection.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
role of skin cleansing and prophylactic antibiotics given to women undergoing a cesarean section for reducing the incidence of postpartum infectious morbidity
Time Frame: 2 weeks following cesarean section
|
2 weeks following cesarean section
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MiniaMUH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Postpartum Infectious Morbidity in Cesarean Section Delivery
-
NCT03402685CompletedCesarean Section Complications | Cesarean Delivery Affecting Newborn | Cesarean Delivery Affecting Fetus
-
NCT06506721RecruitingCesarean Section | Delivery, Obstetric | Obstetric Delivery
-
NCT07322419RecruitingCesarean Delivery | Spinal Anesthesia for Cesarean Section
-
NCT01190163TerminatedCesarean Section | Vaginal Delivery
-
NCT07567495Not yet recruitingDexmedetomidine | Postoperative Analgesia | Cesarean Delivery | Cesarean Delivery; Neuraxial Opioids | Clonidine | Spinal Anesthesia for Cesarean Section
-
NCT07369700Enrolling by invitationCesarean Section Complications | Surgical Site Infection Following Cesarean Delivery
-
NCT04955847RecruitingCesarean Section | Vaginal Delivery | Induction of Labor
-
NCT03298594CompletedAttempted Vaginal Delivery After a Cesarean Section
-
NCT07192718Enrolling by invitationCesarean Section Complications | Postpartum Care
-
NCT02912403WithdrawnNormotensive Postpartum Cesarean Section Patients
Clinical Trials on Women undergo cesarean section delivery
-
NCT05373563CompletedFailed VBAC (Vaginal Birth After Cesarean)
-
NCT06528340CompletedCesarean Section Complications | Labor Complication | Premature | Delivery Complication | Advanced Maternal Age Pregnancy | Complication of Labor and Delivery | Delivery Complications Affecting Fetus / Newborn | Delivery;Complicated;Liveborn
-
NCT00501501Completed
-
NCT06491368CompletedCesarean Section Complications
-
NCT07387380CompletedCesarean Delivery Procedures
-
NCT01766193CompletedUrinary Incontinence | Uterine Prolapse | Fecal Incontinence
-
NCT07250412Enrolling by invitationPlacenta Accrete Spectrum